QL1701
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for QL1701, covering 2024-04-23 to 2024-04-23. Get the full timeline:
Most recent: Clinical Trial Update: A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer [Phase 3]